Pharmacokinetics of an Oral Drug (Acetaminophen) Administered at Various Times in Relation to Subcutaneous Injection of Exenatide (Exendin‐4) in Healthy Subjects
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Exenatide is an incretin mimetic with potential glucoregulatory activity in type 2 diabetes. This randomized, single‐blind, placebo‐controlled 6‐way crossover study assessed exenatide's effect on acetaminophen pharmacokinetics. Of 40 randomized healthy subjects, 39 completed the study. On the placebo day, acetaminophen (1000 mg) was ingested and placebo injected subcutaneously at 0 hours. On exenatide days, acetaminophen was ingested at −1, 0, +1, +2, and +4 hours, relative to the 10 μg exenatide injected subcutaneously at 0 hours. With exenatide injection, mean plasma acetaminophen AUC0–12 h values were reduced by 11% to 24% (vs placebo). Peak plasma acetaminophen concentrations were similar for the −1‐hour and placebo groups and reduced by 37% to 56% at other times. The most frequent adverse events were generally mild to moderate nausea and vomiting. Exenatide treatment concurrent with or preceding acetaminophen ingestion slowed acetaminophen absorption but had minimal effect on the extent of absorption.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Co-administration of exenatide [13], lixisenatide [36], liraglutide [19], dulaglutide [32, 38] or semaglutide [27, 40] resulted in decreased Cmax and delayed tmax of acetaminophen (Table 3).”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [13]
In the citing paper
“Fair quality of methodology was considered in studies that enrolled only male subjects (“population” category) [14, 22, 25, 26, 28] or when blood sampling did not coincide with a steady state of an investigated drug [13–17, 19, 24].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [13]
Citations
Cites
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 2×
“This was true for both solid(13,18) and liquid(19) gastric emptying and for healthy subjects(17,18,20) as well as those with type 2 diabetes.(13) Slowing of gastric emptying by exenatide has also been examined.”
BackgroundResultPharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065 · cited 1×
“Moreover, many available therapeutic agents have undesirable side effects, such as weight gain, hypoglycemia, and edema, which can discourage patient compliance and hence impede glycemic control.(3,4) Exenatide (exendin-4), currently under clinical evaluation for glycemic control in patients with type 2 diabetes, is a…”
BackgroundImprovement of Gastric Emptying in Diabetic Gastroparesis by Erythromycin: Preliminary Studies
Janssens, J., Peeters, T. L., Vantrappen, G., Tack, J., Urbain, J. L., De Roo, M., Muls, E., & Bouillon, R. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004123221502 · Cited by 753
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Kolterman, O. G., Buse, J. B., Fineman, M. S., Gaines, E., Heintz, S., Bicsak, T. A., Taylor, K., Kim, D., Aisporna, M., Wang, Y., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021545 · Cited by 552 · cited 1×
“Like GLP1, exenatide slowed gastric emptying in healthy subjects(12) and subjects with type 2 diabetes.(5) These previous studies formed the basis for the more extensive examination of exenatide’s effects on gastric emptying described here.”
ResultSelf-citationClinical Pharmacokinetics of Paracetamol
Forrest, J. A. H., Clements, J. A., & Prescott, L. F. (1982) · Clinical Pharmacokinetics · doi:10.2165/00003088-198207020-00001 · Cited by 493 · cited 1×
“In this study, administration of exenatide caused slowing, but not cessation, of gastric emptying, as measured by acetaminophen absorption.(28) The rate of gastric emptying is a major determinant of glycemic control in both healthy individuals and those with diabetes.”
BackgroundRelationship between oral glucose tolerance and gastric emptying in normal healthy subjects
Horowitz, M., Edelbroek, M. A. L., Wishart, J. M., & Straathof, J. W. (1993) · Diabetologia · doi:10.1007/bf00400362 · Cited by 469
Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
Edwards, C. M. B., Stanley, S. A., Davis, R., Brynes, A. E., Frost, G. S., Seal, L. J., Ghatei, M. A., & Bloom, S. R. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.1.e155 · Cited by 464 · cited 1×
“These actions include glucose-dependent enhancement of insulin secretion,(5-11) suppression of inappropriately high glucagon secretion,(5,6,8,10,11) slowing of gastric emptying,(5,6,8,12) reduction of food intake and body weight,(8,10,12-15) and an increase in β-cell mass (animal studies) and function.(6,8,10,12,16) P…”
BackgroundNielsen, L. L., Young, A. A., & Parkes, D. G. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2003.10.028 · Cited by 457 · cited 1×
“These actions include glucose-dependent enhancement of insulin secretion,(5-11) suppression of inappropriately high glucagon secretion,(5,6,8,10,11) slowing of gastric emptying,(5,6,8,12) reduction of food intake and body weight,(8,10,12-15) and an increase in β-cell mass (animal studies) and function.(6,8,10,12,16) P…”
BackgroundYoung, A. A., Gedulin, B. R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B., & Denaro, M. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1026 · Cited by 440
Kolterman, O. G., Kim, D. D., Shen, L., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. D. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.2.173 · Cited by 434
Self-citationSchvarcz, E., Palmer, M., Aman, J., Horowitz, M., Stridsberg, M., & Berne, C. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70080-5 · Cited by 416 · cited 1×
“One study found that gastric-emptying rates were increased more in patients with diabetes than in healthy subjects when clamped at hyperglycemic conditions.(32) This may indicate that gastric emptying had become maladaptive in these patients, even inappropriately accelerated, rendering them unable to adequately regula…”
BackgroundGastric and oesophageal emptying in patients with Type 2 (non-insulin-dependent) diabetes mellitus
Horowitz, M., Harding, P. E., Maddox, A. F., Wishart, J. M., Akkermans, L. M. A., Chatterton, B. E., & Shearman, D. J. C. (1989) · Diabetologia · doi:10.1007/bf00265086 · Cited by 392
Fineman, M. S., Bicsak, T. A., Shen, L. Z., Taylor, K., Gaines, E., Varns, A., Kim, D., & Baron, A. D. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2370 · Cited by 353 · cited 1×
“These actions include glucose-dependent enhancement of insulin secretion,(5-11) suppression of inappropriately high glucagon secretion,(5,6,8,10,11) slowing of gastric emptying,(5,6,8,12) reduction of food intake and body weight,(8,10,12-15) and an increase in β-cell mass (animal studies) and function.(6,8,10,12,16) P…”
BackgroundSelf-citationRelationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus
Horowitz, M., Maddox, A., Wishart, J., Harding, P., Chatterton, B., & Shearman, D. C. (1991) · European Journal of Nuclear Medicine · doi:10.1007/bf00186645 · Cited by 326
Gastric emptying in diabetes: clinical significance and treatment
Horowitz, M., O’Donovan, D., Jones, K. L., Feinle, C., Rayner, C. K., & Samsom, M. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00658.x · Cited by 308
Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats
Szayna, M. (2000) · Endocrinology · doi:10.1210/en.141.6.1936 · Cited by 303
GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans
Näslund, E., Bogefors, J., Skogar, S., Grybäck, P., Jacobsson, H., Holst, J. J., & Hellström, P. M. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.277.3.r910 · Cited by 284
Egan, J. M. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.3.1282 · Cited by 256
Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro
Parkes, D. G., Pittner, R., Jodka, C., Smith, P., & Young, A. (2001) · Metabolism · doi:10.1053/meta.2001.22519 · Cited by 241
Gastric emptying in patients with insulin-requiring diabetes mellitus.
Keshavarzian, A., Fl, I., & Vaeth, J. (1987) · PubMed · Cited by 201
Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1
Holst, J. J. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.328 · Cited by 155 · cited 1×
“These actions include glucose-dependent enhancement of insulin secretion,(5-11) suppression of inappropriately high glucagon secretion,(5,6,8,10,11) slowing of gastric emptying,(5,6,8,12) reduction of food intake and body weight,(8,10,12-15) and an increase in β-cell mass (animal studies) and function.(6,8,10,12,16) P…”
BackgroundMourot, J., Thouvénot, P., Couet, C., Antoine, J. M., Krobicka, A., & Debry, G. (1988) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/48.4.1035 · Cited by 132
Highly variable gastric emptying in patients with insulin dependent diabetes mellitus.
Nowak, T. V., Johnson, C. P., Kalbfleisch, J. H., Roza, A. M., Wood, C. M., Weisbruch, J. P., & Soergel, K. H. (1995) · Gut · doi:10.1136/gut.37.1.23 · Cited by 128
Effect of altered gastric emptying and gastrointestinal motility on metformin absorption
Marathe, Wen, Y., Norton, J., Greene, D. S., Barbhaiya, R. H., & Wilding, I. R. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00264.x · Cited by 124
Gonlachanvit, S., Hsu, C.-W., Boden, G. H., KNIGHT, L. C., Maurer, A. H., Fisher, R. S., & Parkman, H. P. (2003) · Digestive Diseases and Sciences · doi:10.1023/a:1022528414264 · Cited by 119
Gastrointestinal Transit Disorders in Patients with Insulin-Treated Diabetes mellitus
Wegener, M., Börsch, G., Schaffstein, J., Luerweg, C., & Leverkus, F. (1990) · Digestive Diseases · doi:10.1159/000171237 · Cited by 116
Näslund, E. (2000) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655200750023930 · Cited by 110 · cited 1×
“acetaminophen absorption is primarily determined by gastric emptying, acetaminophen absorption has been used as a surrogate measure of gastric emptying,(12,25) as in this study, and has been found to be equivalent to scintigraphic methods.(26) The primary endpoint of this study was to measure the effects of exenatide…”
Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes.
Nielsen, L. L., & Baron, A. (2003) · PubMed · Cited by 82
Gastric emptying in diabetes mellitus: relationship to blood-glucose control
Kong, M.-F., & Horowitz, M. (1999) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(18)30062-4 · Cited by 80
Pharmacokinetic Drug Interactions with Gastrointestinal Motility Modifying Agents
Greiff, J. M. C., & Rowbotham, D. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199427060-00004 · Cited by 72 · cited 1×
“Absorption of other medications is also affected by gastric emptying, including other analgesic drugs (morphine), hypnotic agents (lorazepam), and antibiotics (tetracycline and amoxicillin).(41) Some medications in themselves alter gastric emptying and, when used to treat patients with diabetes, may also affect glucos…”
BackgroundBateman, D. N. (1986) · European Journal of Clinical Pharmacology · doi:10.1007/bf00614304 · Cited by 71
Lyrenås, E. B., Olsson, E. H. K., Arvidsson, U. C., Örn, T. J., & Spjuth, J. H. (1997) · Diabetes Care · doi:10.2337/diacare.20.3.413 · Cited by 70
Kong, M.-F. S.-C., Macdonald, I. A., & Tattersall, R. B. (1996) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199602)13:2<112::aid-dia37>3.0.co;2-h · Cited by 69
Phillips, W. T., Schwartz, J. G., & McMahan, C. A. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01296773 · Cited by 49
Gandia, P., Bareille, M., Saivin, S., Le‐Traon, A. P., Lavit, M., Guell, A., & Houin, G. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003257229 · Cited by 48
Long-term Effects of Pregnancy on Diabetic Complications
Kaaja, R., Sjöberg, L., Hellsted, T., Immonen, I., Sane, T., & Teramo, K. (1996) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199602)13:2<165::aid-dia61>3.0.co;2-e · Cited by 48
The influence of gastrointestinal transit on drug absorption in healthy volunteers.
Riley, S., Sutcliffe, F., Kim, M., Kapas, M., Rowland, M., & Turnberg, L. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04104.x · Cited by 35 · cited 1×
“Gastric emptying is also of interest as it modulates the absorption of orally administered drugs, including metformin,(16) droxicam,(22) diazepam,(23) and salicylic acid.(24) Absorption of other medications is also affected by gastric emptying, including other analgesic drugs (morphine), hypnotic agents (lorazepam), a…”
BackgroundUpdate: pharmaceuticals and gastric emptying.
Chaudhuri, T. K., & FINK, S. (1990) · PubMed · Cited by 19
Näslund, E., Bogefors, J., Grybäck, P., Bjellerup, P., Jacobsson, H., Holst, J. J., & Hellström, P. M. (2001) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655201750065906 · Cited by 18
E. Näslund, J. B. (2001) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520121133 · Cited by 15
The Influence of Gastric Emptying on Droxicam Pharmacokinetics
Sánchez, J. D. G., Martínez, L., García-Barbal, J., Roser, R., Bartlett, A., & Sagarra, R. (1989) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1989.tb03409.x · Cited by 14
Research works printed but not linked: 4
- 10.1210/jcem.87.3.8337 · doi:10.1210/jcem.87.3.8337 · Paper page
- 10.1210/endo.141.6.7490 · doi:10.1210/endo.141.6.7490 · Paper page
- Jodka C, 1998, Exendin‐4 potently stimulates gastric emptying in rats [abstract], Diabetes, 47, A403
- Soon D, 2004, Effect of exenatide on digoxin pharmacokinetics, Clin Exp Pharmacol Physiol., 31, A65
Cited by
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.07.003 · Cited by 261
Self-citationLiraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0343-6 · Cited by 217
Verspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 196
Glycaemic control in type 2 diabetes: Targets and new therapies
Tahrani, A. A., Piya, M. K., Kennedy, A., & Barnett, A. H. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.001 · Cited by 190
Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes
Cervera, A., Wajcberg, E., Sriwijitkamol, A., Fernandez, M., Zuo, P., Triplitt, C., Musi, N., DeFronzo, R. A., & Cersosimo, E. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00030.2008 · Cited by 157
“On the basis of the plasma acetaminophen levels, which closely reflect the liquid component of the meal (1), 58% of the glucose retained in the splanchnic area could be accounted for by slowing of gastric emptying.”
BackgroundResult
Metadata
- Authors
- Blase, E., Taylor, K., Gao, H., Wintle, M., & Fineman, M.
- Corresponding author
- Fineman, Mark
- ORCID
- Fineman, Mark
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2005-05
- Volume
- 45
- Issue
- 5
- Pages
- 570-577
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2001592873
- Cited by
- 82
- References
- 46
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 1 · 2020: 1 · 2019: 4 · 2018: 3 · 2017: 1 · 2016: 1 · 2015: 6 · 2014: 4 · 2013: 1 · 2012: 9
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- exenatide, exendin-4, paracetamol, drug-drug interactions, pharmacokinetics, oral drug absorption, subcutaneous administration, type 2 diabetes, glucoregulation, nausea and vomiting
- MeSH terms
- Exenatide, Acetaminophen, Administration, Oral, Adolescent, Adult, Aged, Drug Interactions, Female, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Peptides, Venoms, Single-Blind Method, Cross-Over Studies, Analgesics, Non-Narcotic, Area Under Curve
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.